John Hilterman/LinkedIn
Nov 5, 2025, 05:09
Rethinking Anticoagulants in Hospice
John Hilterman, Business Development Manager at Wise Hospice Option, posted on LinkedIn:
”Safer care starts with clearer insight.
For many hospice patients, the goal shifts from prevention to comfort – and that means re-evaluating medications like anticoagulants and antiplatelets.
Our latest Hospice Pharmacist’s Brief outlines when deprescribing is clinically appropriate, how to manage risk, and ways to align therapy with quality-of-life goals.”
Read more here.
Keep up with Hemostasis Today.
-
May 5, 2026, 16:28Nikolay Novitski: A New Era in Cardiovascular Prevention
-
May 5, 2026, 16:23Satyam Arora: Best Abstract Award in Pediatric Apheresis at ASFA 2026 Congress
-
May 5, 2026, 16:17Hannah Omunakwe: Your Sick Child Has a Clot. Did You See That Coming?
-
May 5, 2026, 15:57Venous Thromboembolism Risk in Pregnancy and the Postpartum Period – NBCA
-
May 5, 2026, 15:28Soumen Bhattacharyya: Hyperhomocysteinemia and Thrombosis – What Clinicians Should Know
-
May 5, 2026, 15:06Wolfgang Miesbach: How Should We Approach GI Angiodysplasia in VWD?
-
May 5, 2026, 14:48What Constitutes High Risk for Venous Thromboembolism? – JTH
-
May 5, 2026, 14:41How Real-Time Data, Rehabilitation Registries, and Patient-Reported Outcomes Can Transform Practice – European Stroke Organisation
-
May 5, 2026, 14:41Driving National Change for Bleeding Disorders – WFH